BullFrog has exclusive, worldwide license agreements with major U.S. biomedical institutions to advance promising drug candidates.
Our industry-leading bfLEAP™ technology platform has the potential to streamline and de-risk multiple steps of the drug development process.
Demonstrated Success Advancing In-Licensed Assets
Discovery
Preclinical
Phase I
Phase II
Phase III